Oriental Aromatics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 24, 2025, 12:09 am

Competitors of Oriental Aromatics Ltd

All Competitor Stocks of Oriental Aromatics Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:13 am

Below is a detailed analysis of the quarterly data for Oriental Aromatics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 253.16 Cr.. The value appears strong and on an upward trend. It has increased from 222.57 Cr. (Dec 2024) to 253.16 Cr., marking an increase of 30.59 Cr..
• For Expenses, as of Mar 2025, the value is 233.89 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 200.02 Cr. (Dec 2024) to 233.89 Cr., marking an increase of 33.87 Cr..
• For Operating Profit, as of Mar 2025, the value is 19.27 Cr.. The value appears to be declining and may need further review. It has decreased from 22.55 Cr. (Dec 2024) to 19.27 Cr., marking a decrease of 3.28 Cr..
• For OPM %, as of Mar 2025, the value is 7.61%. The value appears to be declining and may need further review. It has decreased from 10.13% (Dec 2024) to 7.61%, marking a decrease of 2.52%.
• For Other Income, as of Mar 2025, the value is 0.24 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Dec 2024) to 0.24 Cr., marking an increase of 0.15 Cr..
• For Interest, as of Mar 2025, the value is 8.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.36 Cr. (Dec 2024) to 8.62 Cr., marking an increase of 2.26 Cr..
• For Depreciation, as of Mar 2025, the value is 7.23 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.40 Cr. (Dec 2024) to 7.23 Cr., marking an increase of 0.83 Cr..
• For Profit before tax, as of Mar 2025, the value is 3.66 Cr.. The value appears to be declining and may need further review. It has decreased from 9.88 Cr. (Dec 2024) to 3.66 Cr., marking a decrease of 6.22 Cr..
• For Tax %, as of Mar 2025, the value is 60.93%. The value appears to be increasing, which may not be favorable. It has increased from 27.73% (Dec 2024) to 60.93%, marking an increase of 33.20%.
• For Net Profit, as of Mar 2025, the value is 1.42 Cr.. The value appears to be declining and may need further review. It has decreased from 7.14 Cr. (Dec 2024) to 1.42 Cr., marking a decrease of 5.72 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.42. The value appears to be declining and may need further review. It has decreased from 2.12 (Dec 2024) to 0.42, marking a decrease of 1.70.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:34 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:35 am

Below is a detailed analysis of the balance sheet data for Oriental Aromatics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 17.00 Cr..
• For Reserves, as of Mar 2025, the value is 646.00 Cr.. The value appears strong and on an upward trend. It has increased from 616.00 Cr. (Mar 2024) to 646.00 Cr., marking an increase of 30.00 Cr..
• For Borrowings, as of Mar 2025, the value is 353.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 206.00 Cr. (Mar 2024) to 353.00 Cr., marking an increase of 147.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 129.00 Cr.. The value appears to be improving (decreasing). It has decreased from 157.00 Cr. (Mar 2024) to 129.00 Cr., marking a decrease of 28.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,145.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 995.00 Cr. (Mar 2024) to 1,145.00 Cr., marking an increase of 150.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 270.00 Cr. (Mar 2024) to 480.00 Cr., marking an increase of 210.00 Cr..
• For CWIP, as of Mar 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2024) to 5.00 Cr., marking a decrease of 168.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 660.00 Cr.. The value appears strong and on an upward trend. It has increased from 551.00 Cr. (Mar 2024) to 660.00 Cr., marking an increase of 109.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,145.00 Cr.. The value appears strong and on an upward trend. It has increased from 995.00 Cr. (Mar 2024) to 1,145.00 Cr., marking an increase of 150.00 Cr..

Notably, the Reserves (646.00 Cr.) exceed the Borrowings (353.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Oriental Aromatics Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.20. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 10.20, marking an increase of 7.49.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.20. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 10.20, marking an increase of 7.49.
• For Cash EPS (Rs.), as of Mar 25, the value is 17.24. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 17.24, marking an increase of 8.65.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 197.00. It has increased from 187.90 (Mar 24) to 197.00, marking an increase of 9.10.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 197.00. It has increased from 187.90 (Mar 24) to 197.00, marking an increase of 9.10.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 275.83. It has increased from 248.53 (Mar 24) to 275.83, marking an increase of 27.30.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 28.72. This value is within the healthy range. It has increased from 16.11 (Mar 24) to 28.72, marking an increase of 12.61.
• For PBIT / Share (Rs.), as of Mar 25, the value is 21.69. This value is within the healthy range. It has increased from 10.23 (Mar 24) to 21.69, marking an increase of 11.46.
• For PBT / Share (Rs.), as of Mar 25, the value is 14.15. This value is within the healthy range. It has increased from 4.18 (Mar 24) to 14.15, marking an increase of 9.97.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.20. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 10.20, marking an increase of 7.49.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.20. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 10.20, marking an increase of 7.49.
• For PBDIT Margin (%), as of Mar 25, the value is 10.41. This value is within the healthy range. It has increased from 6.48 (Mar 24) to 10.41, marking an increase of 3.93.
• For PBIT Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 10. It has increased from 4.11 (Mar 24) to 7.86, marking an increase of 3.75.
• For PBT Margin (%), as of Mar 25, the value is 5.12. This value is below the healthy minimum of 10. It has increased from 1.68 (Mar 24) to 5.12, marking an increase of 3.44.
• For Net Profit Margin (%), as of Mar 25, the value is 3.69. This value is below the healthy minimum of 5. It has increased from 1.08 (Mar 24) to 3.69, marking an increase of 2.61.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.69. This value is below the healthy minimum of 8. It has increased from 1.08 (Mar 24) to 3.69, marking an increase of 2.61.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.17. This value is below the healthy minimum of 15. It has increased from 1.43 (Mar 24) to 5.17, marking an increase of 3.74.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.38. This value is below the healthy minimum of 10. It has increased from 4.80 (Mar 24) to 9.38, marking an increase of 4.58.
• For Return On Assets (%), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 5. It has increased from 0.91 (Mar 24) to 2.99, marking an increase of 2.08.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 0.2. It has increased from 0.08 (Mar 24) to 0.12, marking an increase of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.53. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.53, marking an increase of 0.21.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.86. It has increased from 0.84 (Mar 24) to 0.86, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.75. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.75, marking a decrease of 0.15.
• For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.75, marking a decrease of 0.15.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.92. This value is below the healthy minimum of 4. It has increased from 1.65 (Mar 24) to 1.92, marking an increase of 0.27.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.48 (Mar 24) to 0.00, marking a decrease of 18.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.82 (Mar 24) to 0.00, marking a decrease of 5.82.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.52 (Mar 24) to 0.00, marking a decrease of 81.52.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.18 (Mar 24) to 0.00, marking a decrease of 94.18.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.81. This value is within the healthy range. It has increased from 2.66 (Mar 24) to 3.81, marking an increase of 1.15.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.35. This value is below the healthy minimum of 3. It has increased from 1.45 (Mar 24) to 2.35, marking an increase of 0.90.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,267.80. It has increased from 1,198.42 (Mar 24) to 1,267.80, marking an increase of 69.38.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 1.37, marking a decrease of 0.06.
• For EV / EBITDA (X), as of Mar 25, the value is 13.12. This value is within the healthy range. It has decreased from 22.10 (Mar 24) to 13.12, marking a decrease of 8.98.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 24) to 0.99, marking a decrease of 0.21.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 81.51 (Mar 24) to 0.00, marking a decrease of 81.51.
• For Price / BV (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has decreased from 1.59 (Mar 24) to 1.40, marking a decrease of 0.19.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 24) to 0.99, marking a decrease of 0.21.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness